Paper - WANFANG MED ONLINE

You Position: Home > Paper

慢性阻塞性肺疾病共病评估工具及其应用的研究进展

( views:31, downloads:682 )

Author:: No author available

Journal Title:: Chinese Journal of Tuberculosis and Respiratory Diseases

Issue:: 9

DOI:: 10.3760/cma.j.issn.1001-0939.2018.09.020

Key Word:: No keyword available

Abstract：慢性阻塞性肺疾病(慢阻肺)是呼吸系统常见的慢性疾病,其致残率、病死率高,社会经济负担重,是全球重要的公共卫生问题[1-2].预计到2020年,慢阻肺将成为全球第3大死因,疾病负担将位居全球第五位[3].慢阻肺通常与心血管疾病、胃食管反流疾病、骨质疏松和抑郁等[4-6]疾病共同存在,当慢阻肺与一种或多种疾病共同存在于个体时[7],称为慢阻肺共病,其发生率为90％～ 98％[4,8-11],给患者的健康及经济造成额外的负担.慢阻肺共病的有效评估,有助于临床医护人员了解患者疾病的严重程度,为制定最佳治疗方案与护理措施提供依据.本文对慢阻肺共病评估工具及其临床价值进行综述,以期为临床工作提供参考.

Reference

[1]V. Areias,S. Carreira,M. Anciães,etc.Co-morbidities in patients with gold stage 4 chronic obstructive pulmonary disease[J].2014,20(1).
[2]Noteboom, B.,Jenkins, S.,Maiorana, A.,etc.Comorbidities and Medication Burden in Patients With Chronic Obstructive Pulmonary Disease Attending Pulmonary Rehabilitation[J].2014,34(1).
[3]Shaya FT,Scharf SM,Lin PJ.Economic implications of comorbid conditions among Medicaid beneficiaries with COPD.[J].2010,104(5).
[4]Laura Miranda de Oliveira, Caram,Renata, Ferrari,Cristiane Roberta, Naves,etc.Risk factors for cardiovascular disease in patients with COPD: mild-to-moderate COPD versus severe-to-very severe COPD.[J].1900,42.
[5]A R, Feinstein.The Pre-Therapeutic Classification of Co-Morbidity in Chronic Disease.[J].1970,23(7).
[6]Budweiser,S.,Harlacher,M.,Pfeifer,M.,etc.Co-morbidities and hyperinflation are independent risk factors of all-cause mortality in very severe COPD[J].2014,11(4).
[7]Nishimura,M.,Barnes,P.J.,Anzueto,A.,etc.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease GOLD executive summary[J].2013,187(4).
[8]Vanfleteren,L.E.G.W.,Spruit,M.A.,Groenen,M.,etc.Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease[J].2013,187(7).
[9]Giorgio, Fumagalli,Fabrizio, Fabiani,Silvia, Forte,etc.INDACO project: a pilot study on incidence of comorbidities in COPD patients referred to pneumology units.[J].2013,8(1).
[10]Hsieh, Ming-Han,Lee, Charles Tzu-Chi,Tsai, Pei-Jung,etc.Chronic obstructive pulmonary disease and anxiety disorders: a nationwide population-based study in Taiwan.[J].2016.
[11]Ming-Chen, Chan,Ching-Heng, Lin,Yu Ru, Kou.Hyperlipidemia in COPD is associated with decreased incidence of pneumonia and mortality: a nationwide health insurance data-based retrospective cohort study.[J].2016.
[12]M E, Charlson,P, Pompei,K L, Ales,etc.A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.[J].1987,40(5).
[13]Braendli O,Schunemann HJ,Montori VM,etc.Measurement of agreement on health-related quality of life changes in response to respiratory rehabilitation by patients and physicians--a prospective study.[J].2004,98(12).
[14]Chung-Han, Ho,Yi-Chen, Chen,Chin-Chen, Chu,etc.Age-adjusted Charlson comorbidity score is associated with the risk of empyema in patients with COPD.[J].2017,96(36).
[15]Pedro Almagro,Joan B. Soriano,Francisco J. Cabrera,etc.Short- and Medium-term Prognosis in Patients Hospitalized for COPD ExacerbationThe CODEX Index[J].2014,145(5).
[16]Chen, Wenjia,FitzGerald, J. Mark,Sin, Don D.,etc.Excess economic burden of comorbidities in COPD: a 15-year population-based study[J].2017,50(1).
[17]Bourke,S.C.,Gibson,J.,Steer,J..The DECAF score: Predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease[J].2012,67(11).
[18]Chubachi, Shotaro,Sato, Minako,Kameyama, Naofumi,etc.Identification of five clusters of comorbidities in a longitudinal Japanese chronic obstructive pulmonary disease cohort[J].2016,117.
[19]Hansel, Nadia N.,Drummond, M. Bradley,Putcha, Nirupama,etc.Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management[J].2015,36(4).
[20]Luis, García-Olmos,Angel, Alberquilla,Victoria, Ayala,etc.Comorbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional study.[J].2013,14.
[21]Charlson, Mary,Wells, Martin T.,Ullman, Ralph,etc.The Charlson Comorbidity Index Can Be Used Prospectively to Identify Patients Who Will Incur High Future Costs.[J].2014,9(12).
[22]R W, Dal Negro,L, Bonadiman,P, Turco.Prevalence of different comorbidities in COPD patients by gender and GOLD stage.[J].2015,10(1).
[23]Cote,C.,Pinto-Plata,V.,Divo,M.,etc.Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease[J].2012,186(2).
[24]Saiprasad, Narsingam,Andrew L, Bozarth,Asem, Abdeljalil.Updates in the management of stable chronic obstructive pulmonary disease.[J].2015,127(7).
[25]Osama M Gado,Lamia A Basiony,Mahasen M Ibrahim,etc.Anxiety-depressive Symptoms in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Impact on Outcome[J].2015,4(2).
[26]Sanchez LS,Soler-Cataluna JJ,Martinez-Garcia MA,etc.Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients.[J].2009,103(5).
[27]M, Charlson,T P, Szatrowski,J, Peterson,etc.Validation of a combined comorbidity index.[J].1994,47(11).
[28]DeTorres,J.P.,Casanova,C.,Marín,J.M.,etc.Prognostic evaluation of copd patients: Gold 2011 versus bode and the copd comorbidity index cote[J].2014,69(9).
[29]Frei, Anja,Muggensturm, Patrick,Putcha, Nirupama,etc.Five comorbidities reflected the health status in patients with chronic obstructive pulmonary disease: the newly developed COMCOLD index[J].2014,67(8).
[30]Daisuke, Inoue,Reiko, Watanabe,Ryo, Okazaki.COPD and osteoporosis: links, risks, and treatment challenges.[J].2016.
[31]何权瀛.2015年修订版慢性阻塞性肺疾病全球防治创议简介[J].2015,(2).